24
[ad_1]
New Delhi: Drug biggie Sanofi, with marquee brands including pain and inflammation relief drug Combiflam, anti-infective Allegra and anti-diabetic Lantus, is accelerating its “lean-in” strategy in India, by fast-tracking a robust pipeline, which includes expanding its core diabetes portfolio in India. Sanofi is implementing an accelerated growth plan, ‘India for India’ to gear up for the future and strengthen its India footprint, Rodolfo Hrosz, the company’s managing director said.
Unlike certain MNCs, it has no plans to divest legacy brands in the country, he told TOI in an interview, adding, “India is important for us, we value the talent pool and innovation (here)”.
The comments are significant, coming close on the heels of Sanofi’s recent back-to-back partnerships with three domestic firms — Cipla, Emcure and Dr Reddy’s — for its legacy brands and vaccines. The deals raised speculation about the company’s future in India, coming at a time when MNCs are reducing exposure and divesting core therapies in the over Rs 2 lakh crore domestic market.
With the renewed strategy, the nearly Rs 3,000 crore company, which has been “under-represented in India” could match the pace of the market, and even grow faster than the industry, he added. Sanofi India grew only a strong single-digit in the past.
“Though we have established a robust footprint over the last 68 years (in India), it isn’t the one we need for the future, hence we decided to reset it in the beginning of 2023 to enable growth,’’ Hrosz said.
“The renewed strategy focuses on two objectives — first, maximising access to Sanofi’s existing established portfolio in India… Second, “fast-tracking a robust product pipeline by bringing best-in-class innovations into India,” he added.
Unlike certain MNCs, it has no plans to divest legacy brands in the country, he told TOI in an interview, adding, “India is important for us, we value the talent pool and innovation (here)”.
The comments are significant, coming close on the heels of Sanofi’s recent back-to-back partnerships with three domestic firms — Cipla, Emcure and Dr Reddy’s — for its legacy brands and vaccines. The deals raised speculation about the company’s future in India, coming at a time when MNCs are reducing exposure and divesting core therapies in the over Rs 2 lakh crore domestic market.
With the renewed strategy, the nearly Rs 3,000 crore company, which has been “under-represented in India” could match the pace of the market, and even grow faster than the industry, he added. Sanofi India grew only a strong single-digit in the past.
“Though we have established a robust footprint over the last 68 years (in India), it isn’t the one we need for the future, hence we decided to reset it in the beginning of 2023 to enable growth,’’ Hrosz said.
“The renewed strategy focuses on two objectives — first, maximising access to Sanofi’s existing established portfolio in India… Second, “fast-tracking a robust product pipeline by bringing best-in-class innovations into India,” he added.
We also published the following articles recently
Sanofi and Cipla tie up to expand reach of CNS medicines
Sanofi India and Cipla collaborate for exclusive distribution of CNS product range in India. Cipla to distribute Sanofi’s CNS brands, including Frisium. Rodolfo Hrosz, Sanofi India’s Managing Director, praises CNS products. Achin Gupta, Cipla’s CEO, focuses on patient value.
Sanofi India and Cipla collaborate for exclusive distribution of CNS product range in India. Cipla to distribute Sanofi’s CNS brands, including Frisium. Rodolfo Hrosz, Sanofi India’s Managing Director, praises CNS products. Achin Gupta, Cipla’s CEO, focuses on patient value.
Dr Reddys to distribute Sanofis vaccines
Dr Reddy’s partners with Sanofi Healthcare India to distribute MNCs vaccine brands in India. Sales of approx. Rs 426 crore position them second among vaccine players. Preeti Futnani emphasizes commitment to India.
Dr Reddy’s partners with Sanofi Healthcare India to distribute MNCs vaccine brands in India. Sales of approx. Rs 426 crore position them second among vaccine players. Preeti Futnani emphasizes commitment to India.
[ad_2]
Source link
